

# SAPIEN 3 Predictability Campaign

Edwards SAPIEN 3 Transcatheter H

NOW CE MARK APPROVED: THE EDWARDS SAPIEN 3 VALVE

## PREDICTABILITY MAKES THE DIFFERENCE

Only the Edwards SAPIEN balloon-expandable valve family gives you predictable performance and predictable results—patient after patient.

THE EDWARDS ADVANTAGE



Learn more at [TAVipredictability.com](http://TAVipredictability.com)

For professional use. See Instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events. Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Devices Directive 93/42/EEC bear the CE marking of conformity.

Material for distribution only in countries with applicable health authority product registrations. Material not intended for distribution in USA or Japan. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, SAPIEN, and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation. © 2015 Edwards Lifesciences Corporation. All rights reserved. E4014-03-13/THV

Edwards Lifesciences | [www.edwards.com](http://www.edwards.com)  
One Edwards Way | Irvine, California 92614 USA  
In Canada | Spain | China | Brazil | Australia | India



[REDACTED]  
New S3 fluoros

S3 availability announcement

New physician

Addition of S3 into the SAPIEN valve family [REDACTED]

# SAPIEN 3 Predictability Campaign

Edwards SAPIEN 3 Transcatheter Heart Valves

Edwards SAPIEN Transcatheter Heart Valves

EUROPE - ENGLISH

RETURN HOME PREDICTABLE PERFORMANCE PREDICTABLE RESULTS

**PREDICTABILITY MAKES THE DIFFERENCE**

SELECT IMAGES BELOW TO LEARN HOW THE EDWARDS SAPIEN 3 VALVE WAS DESIGNED FOR PREDICTABLE PERFORMANCE

SAPIEN 3 CASES SAPIEN XT CASES

TF FLOUROSCOPIC EXAMPLE 1

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Contact Us | Legal Terms | Privacy Policy | © 2013 Edwards Lifesciences Corporation. All rights reserved. Learn more at [edwards.com/eu](http://edwards.com/eu)

Edwards SAPIEN Transcatheter Heart Valves

RETURN HOME PREDICTABLE PERFORMANCE

SAPIEN XT Valve:  
RESULTS IN **GROUNDBREAKING CLINICAL**  
**TENSIVE PATIENT REGISTRIES**

URGITATION/PARAVALVULAR LEAK—MODERATE/SEVERE AT 30

ORAL! TRANSAPICAL! TRANSAORTIC!



1. Wendler C. 30 day outcomes from the SOURCE XT TAVI post-approval study. Presented at: EuroPCR, May 15-18, 2012; Paris, France.  
2. Romano M. Alternative access for second generation balloon expandable TAVI devices. Results from the SOURCE XT Post Approval in patients treated via transaortic approach. Presented at: EuroPCR, May 15-18, 2012; Paris, France.  
3. Binder K, et al. Transcatheter Aortic Valve Replacement with the SAPIEN 3. A New Balloon-Expandable Transcatheter Heart Valve. JACC Cardiovasc Interv. Vol. 6, No. 3, 2013.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Contact Us | Legal Terms | Privacy Policy | © 2014 Edwards Lifesciences Corporation. All rights reserved.



## SAPIEN 3 App

Edwards SAPIEN 3 Transcatheter H

- Dedicated S3 app
  - All XT, clinical, other assets in current THV Intl App
- SAPIEN 3 launch story
- S3 videos, animations, congress loop
- S3 presentations
- Clinical data
- Email function

